ClinicalTrials.gg
RecruitingNCT06674863Updated Sep 30, 2026

Addressing Health Literacy With a Tailored Survivorship Care Plan

An interventional study of Educational Intervention and Interview in Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma and Stage IVB Prostate Cancer AJCC v8, sponsored by Emory University. Recruiting at 3 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Emory University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Prostatic Neoplasms by Emory University — 7 open to participants now, 9 under way, 1 of them phase 3. Prostatic Neoplasms · Emory University.

Planned enrollment
4th of 25
150 · median 30
Started
2025
with 2 others
No phase
10 of 25
4 open now
Registered
22nd of 25
by date

Among the 25 studies in Prostatic Neoplasms by Emory University, this one is the 4th largest by planned enrollment, is one of 3 that started in 2025, is one of 10 with no phase, and was the 22nd registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

7 of the 25 studies in Prostatic Neoplasms by Emory University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Prostatic Neoplasms by Emory University, or all of them as a file.
02

Study summary

This clinical trial compares the impact of a tailored survivorship care plan (SCP) to a standard SCP on the understanding of and access to survivorship care in black or African American patients with prostate cancer that has not spread to other parts of the body (localized) or that has spread from where it first started (primary site) to a limited number of places in the body (oligometastatic). SCPs summarize treatment history and recommendations for monitoring and maintaining health, and may also include potential long term effects of treatments received. The intention of a SCP is to help patients participate in their own health care. However, many patients have below basic levels of health literacy, meaning, they have a lower ability to obtain, communicate, process and understand basic health information and services to make health decisions. In fact, poor health literacy has been linked with worse quality of life in prostate cancer survivors. A tailored SCP includes the addition of an educational supplement based on lower reading and writing skills (low literacy) and may address health literacy barriers to understanding of treatment options and side effects. A standard SCP uses a template based on the American Society of Clinical Oncology (ASCO) guidelines for prostate cancer. A tailored SCP with low literacy educational supplements may be more effective compared to a standard SCP in improving understanding and access to survivorship care in black or African American patients with localized or oligometastatic prostate cancer.

Read the detailed description

PRIMARY OBJECTIVES:

I. Compare outcomes after patients receive usual care from their providers with a standard SCP and after patients receive tailoring of the SCP with the low literacy educational supplement.

II. To quantify the potential benefit of tailoring the care plan and the educational supplement.

III. Compare providers' assessment of patients':

IIIa. Health literacy; IIIb. Comprehension of survivorship care recommendations; IIIc. Understanding of long term and late effects from treatment; IIId. To measures obtained from patients.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I (INTERVENTION): Patients receive standard SCP during a provider visit and a tailored SCP with a low literacy educational supplement during a structured interview over 30-60 minutes.

GROUP II (CONTROL): Patients receive standard SCP using the prostate cancer ASCO template during a provider visit and undergo a structured interview over 30-60 minutes.

03

Conditions studied

  • Localized Prostate Carcinoma
  • Oligometastatic Prostate Carcinoma
  • Stage IVB Prostate Cancer AJCC v8

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Black and African American men who are disease-free after completing primary surgery and/or radiation treatment for localized or oligometastatic prostate cancer between 1 to 4 years prior to enrollment. (Race/ethnicity per medical records and self report)
  • Patients who are still receiving androgen deprivation therapy following primary radiation with non-palliative intent may be included

Exclusion criteria

Exclusion Criteria:

  • Dementia or cognitive impairment per provider clinical assessment
  • Unable to give in the judgement of the patient's oncology provider
  • Recurrent prostate cancer after primary treatment
  • Less than 18 years of age at the time of informed consent
  • Diagnosis of active second requiring treatment
  • Individuals who are not able to clearly understand English since the outcome measures require understanding of English
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Group I (standard SCP, tailored SCP)

    Patients receive standard SCP during a provider visit and a tailored SCP with a low literacy educational supplement during a structured interview over 30-60 minutes.

    Other: Educational Intervention · Other: Interview · Other: Questionnaire Administration · Other: Supportive Care

  • Active comparator
    Group II (standard SCP)

    Patients receive standard SCP using the prostate cancer ASCO template during a provider visit and undergo a structured interview over 30-60 minutes.

    Other: Interview · Other: Questionnaire Administration · Other: Supportive Care

Interventions

  • OtherEducational Intervention

    Receive a low literacy educational supplement

    Also known as: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational

  • OtherInterview

    Undergo a structured interview

  • OtherQuestionnaire Administration

    Ancillary studies

  • OtherSupportive Care

    Receive standard SCP

    Also known as: Supportive Therapy, Symptom Management, Therapy, Supportive

  • OtherSupportive Care

    Receive a tailored SCP

    Also known as: Supportive Therapy, Symptom Management, Therapy, Supportive

06

What researchers measure

Primary outcomes

  1. Comprehension of survivorship care recommendations and prostate specific antigen surveillance

    Comprehension will be scored as dichotomous variables, correct or incorrect. The proportion of patients who correctly understand after the standard survivorship care plan (SCP) compared to the proportion who correctly understand after the standard SCP + tailoring + educational support will be analyzed using a two-tailed Z-score test for equality of two proportions at a significance level of P \< 0.05.

    Time frame: At baseline and up to 3 month phone call

  2. Comprehension of treatment side effects and late effects

    Comprehension will be scored as dichotomous variables, correct or incorrect. The proportion of patients who correctly understand after the standard SCP compared to the proportion who correctly understand after the standard SCP + tailoring + educational support will be analyzed using a two-tailed Z-score test for equality of two proportions at a significance level of P \< 0.05.

    Time frame: At baseline and up to 3 month phone call

Secondary outcomes

  1. Access to survivorship care for late and long-term side effects

    Will be assessed using the Patients Access Score (PAS). Descriptive statistics will be used to characterize patient access to survivorship care. The difference in mean PAS will be compared between the two arms using a 2 sample t-test. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Linear regression models will be used to identify predictors of access to survivorship care. Parsimonious models will be favored due to the relatively small sample size.

    Time frame: At baseline and up to 3 month phone call

  2. Decision regret

    Descriptive statistics will be used to characterize decision regret. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Parsimonious models will be favored due to the relatively small sample size.

    Time frame: At baseline and up to 3 month phone call

  3. Change in decisional conflict

    The two-sample t-test will be used to evaluate the change in the average decisional conflict score between patients in the control arm (standard SCP) and patients in the intervention arm (standard SCP + tailoring + educational supplement).

    Time frame: At baseline and up to 3 month phone call

  4. Preparedness for survivorship

    Descriptive statistics will be used to characterize preparedness for survivorship. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Parsimonious models will be favored due to the relatively small sample size.

    Time frame: At baseline and up to 3 month phone call

  5. Patient self-efficacy

    Descriptive statistics will be used to characterize patient self-efficacy. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Parsimonious models will be favored due to the relatively small sample size.

    Time frame: At baseline and up to 3 month phone call

07

Study locations

3 of 3 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2029, 49 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 49 months is above that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2024
First posted
Nov 5, 2024
StartActual
Nov 7, 2025
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2030
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Site contacts
Changed at 1 site. See the sites
Show the site
  • Atlanta VA Medical Center · Atlanta, United StatesContact person changed (no phone or email listed)
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Atlanta VA Medical Center · Atlanta, United StatesContact person changed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06674863
Lead sponsor
Emory University
Collaborators
National Cancer Institute (NCI), United States Department of Defense
Responsible party
Viraj Master (Principal Investigator, Emory University) — Principal investigator
First posted
Nov 5, 2024
Start date
Nov 7, 2025
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Sep 30, 2026

Study contacts

Kerry L. Kilbridge, MD, MSc
Contact
Kerry_Kilbridge@DFCI.HARVARD.EDU
617-632-2429
Viraj Master, MD, PhD, FACS
principal investigator · Emory University Hospital/Winship Cancer Institute

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion